During the past 20 years taxomifen has become the most widely prescribed and most successful drug used in the treatment of breast cancer. In this volume, editor V. Craig Jordan provides articles that trace the development, pharmacology and clinical research surrounding this drug which, by the year 2000, could be used to treat as many as one million women annually. Drawing from research conducted by specialists in the US, the UK and Italy, the series of articles describes the clinical testing of tamoxifen, highlighting the benefits. Studies show that tamoxifen lowers cholesterol and can potentially protect women against osteoporosis and fatal coronary heart disease. Equally important is a discussion of side effects and possible drug interactions and how these issues relate to patient concerns. An investigation of the development of a new class of drugs for use after tamoxifen fails provides valuable insights into future treatments, as the contributors consider possible resistance to tamoxifen. This volume provides valuable information for physicians and surgeons who care for patients with breast cancer and for women interested in exploring this therapeutic dimension.
V. Craig Jordan, internationally recognized as an expert on antiestrogens, is professor of cancer pharmacology and director of the Breast Cancer Research Program at Northwestern University. Dr. Jordan has authored numerous articles and edited several books, including the groundbreaking "Estrogen/Antiestrogen Action and Breast Cancer Therapy," also published by the University of Wisconsin Press. Dr. Jordan has guided the development of tamoxifen for more than twenty years in an effort to improve breast cancer treatment and women's health."
The Development of Tamoxifen for Breast Cancer Therapy; Clinical Pharmacology and Endocrinology of Long Term Tamoxifen Therapy; Multisystem Biological and Symptomatic Toxicity of Tamoxifen in Postmenopausal Women; Endocrine Therapy for the Premenopausal Woman; The Nolvadex Adjuvant Trial Organisation (NATO) and the Cancer Research Campaign (CRC) Trial of Adjuvant Tamoxifen Therapy; The Stockholm Adjuvant Tamoxifen Trial; Maintenance Tamoxifen After Induction Postoperative Chemotherapy in Node Positive Breast Cancer Patients; Prolonged Tamoxifen Treatment of Early Breast Cancer - the Experience of the Italian Cooperative Group for Chemo-hormonal Therapy in Early Breast Cancer; Interactions of Tamoxifen with Cytotoxic Chemotherapy for Breast Cancer; Tamoxifen Resistant Growth; A New Approach to Breast Cancer Therapy - Total Oestrogen Ablation with Pure Antioestrogens; Symptomatic Side Effects of Tamoxifen Therapy; Treatment of Breast Cancer with Tamoxifen.